Key Highlights

  • 11.64% is the pre-market decline indicated for MiMedx Group, Inc (NASDAQ:MDXG) on November 17, 2026, with shares indicated at USD 2.81 against a calculated prior close of USD 3.18.
  • 145.93 million shares were outstanding in the latest published data, implying a calculated market Capitalization of about USD 410.06 million at the indicated pre-market price of USD 2.81 per share.
  • 62.3 million USD was third quarter 2026 net sales, down 45% from USD 113.7 million, with a net loss of USD 8.7 million against Net Income of USD 16.7 million a year earlier.
  • 62.58% is the calculated decline from the 52-week high of USD 7.51 to the indicated price, against a 52-week low of USD 3.025 that now sits above the indicated level.

What Moved MiMedx Group, Inc (NASDAQ:MDXG) in Pre-Market Trading on November 17, 2026 (-USD 0.37, -11.64%)

MiMedx Group, Inc (NASDAQ:MDXG) is indicated at USD 2.81 in pre-market trading on Tuesday, November 17, 2026, a pre-market move of -11.64%. The calculated prior close is USD 3.18 (price divided by 0.8836) and the calculated USD move is -USD 0.37. With 145.93 million shares outstanding, the calculated market capitalization is about USD 410.06 million.

The Rationale: No Same-Day Catalyst Identified Following Weak Wound Care Sales for MiMedx Group, Inc (NASDAQ:MDXG)

No company release or filing dated November 17, 2026 was identified in published coverage, so the move is not attributed to a specific event. As general context, on October 28, 2026 the company reported third quarter net sales of USD 62.3 million, with surgical sales up 9% to USD 40.0 million and wound sales down 71% to USD 22.3 million. Adjusted EBITDA was USD 2.1 million compared with USD 35.0 million a year earlier. Full-year 2026 net sales guidance is USD 250 million to USD 260 million, below the prior USD 260 million to USD 290 million. The company is also working through an FTC second request on its pending Sanara MedTech acquisition.

Valuation, Liquidity and Risks for MiMedx Group, Inc (NASDAQ:MDXG)

MiMedx develops placental tissue allografts using its PURION process. Trailing Revenue is USD 303.73 million, down 22.8%, with a trailing net loss of USD 19.19 million, or USD 0.13 per share. Cash and equivalents were USD 120.8 million at September 30, 2026, down from USD 166.1 million at December 31, 2025, and the company repaid its remaining USD 17 million term Loan to end the quarter with no debt. A non-exclusive Patent license with a wound care competitor provides USD 25 million in five equal USD 5 million installments. The Sanara transaction was agreed at USD 35 per share, about USD 350 million in enterprise value, with financing under a Hayfin commitment and possible ticking and termination fees.

Where Things Stand

The indicated pre-market price of USD 2.81 for MiMedx Group, Inc (NASDAQ:MDXG) is 11.64% below a calculated prior close of USD 3.18 on November 17, 2026. The company has about 145.93 million shares, a calculated Market Value near USD 410.06 million, third quarter net sales of USD 62.3 million and cash of USD 120.8 million with no Debt at September 30, 2026. Guidance of USD 250 million to USD 260 million for 2026 and the pending Sanara transaction frame the backdrop. No same-day catalyst was identified, so low-priced Volatility and pre-market illiquidity are general context rather than established causes. Pre-market quotes are indicative until the 9:30 a.m. ET open.